Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K R Hande

Showing results (11-20 of 109) with videos related to

Pageof 11
Sort By:
Analytical Biochemistry|January 1, 1980
A competitive protein binding assay for allopurinol and oxipurinolK R Hande, B A Chabner
Cancer Chemotherapy and Biological Response Modifiers|November 1, 2001
Topoisomerase II inhibitorsT R Toonen, K R Hande
Journal of the Tennessee Medical Association|January 1, 1979
The clinical pharmacology and use of antineoplastic drugsF A Greco, K R Hande
Clinics in Chest Medicine|May 1, 1982
Chemotherapy and radiation therapy for non-small cell lung carcinomaK R Hande, R M Des Prez
Chest|May 1, 1984
Current perspectives in small cell lung cancerK R Hande, R M Des Prez
Seminars in Oncology|February 1, 1997
Paclitaxel, 5-fluorouracil, and folinic acid in metastatic breast cancer: BRE-26, a phase II trialD H Johnson, D Paul, K R Hande
Cancer Treatment Reports|April 1, 1986
Toxicity of doxorubicin metabolites to human marrow erythroid and myeloid progenitors in vitroE N Dessypris, D E Brenner, K R Hande
Stem Cells (Dayton, Ohio)|August 7, 1999
New drugs on the horizon: matrix metalloproteinase inhibitorsM L Rothenberg, A R Nelson, K R Hande
The American Journal of Medicine|January 1, 1984
Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiencyK R Hande, R M Noone, W J Stone
Bulletin Du Cancer|January 1, 1979
Ara-C metabolism: implications for drug resistance and drug interactionsB A Chabner, K R Hande, J C Drake
Pageof 11

Showing results (11-20 of 109) with videos related to

Sort By:
Pageof 11
Analytical Biochemistry|January 1, 1980
A competitive protein binding assay for allopurinol and oxipurinolK R Hande, B A Chabner
Cancer Chemotherapy and Biological Response Modifiers|November 1, 2001
Topoisomerase II inhibitorsT R Toonen, K R Hande
Journal of the Tennessee Medical Association|January 1, 1979
The clinical pharmacology and use of antineoplastic drugsF A Greco, K R Hande
Clinics in Chest Medicine|May 1, 1982
Chemotherapy and radiation therapy for non-small cell lung carcinomaK R Hande, R M Des Prez
Chest|May 1, 1984
Current perspectives in small cell lung cancerK R Hande, R M Des Prez
Seminars in Oncology|February 1, 1997
Paclitaxel, 5-fluorouracil, and folinic acid in metastatic breast cancer: BRE-26, a phase II trialD H Johnson, D Paul, K R Hande
Cancer Treatment Reports|April 1, 1986
Toxicity of doxorubicin metabolites to human marrow erythroid and myeloid progenitors in vitroE N Dessypris, D E Brenner, K R Hande
Stem Cells (Dayton, Ohio)|August 7, 1999
New drugs on the horizon: matrix metalloproteinase inhibitorsM L Rothenberg, A R Nelson, K R Hande
The American Journal of Medicine|January 1, 1984
Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiencyK R Hande, R M Noone, W J Stone
Bulletin Du Cancer|January 1, 1979
Ara-C metabolism: implications for drug resistance and drug interactionsB A Chabner, K R Hande, J C Drake
Pageof 11